← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Omniox, Inc.
San Francisco, CA
$18,183,104
Total funding
10
Grants
Funding over time
peak $2.5M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,183,104 · 10
By mechanism
R44$13,495,329 · 3
R01$2,796,474 · 1
R43$1,891,301 · 6
Investigators at Omniox, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO$1,494,655
R44 · FY2011 · CA
Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier$1,209,149
R44 · FY2017 · NS
Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier$1,115,299
R44 · FY2016 · NS
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$1,032,262
R44 · FY2018 · HD
TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO$1,000,000
R44 · FY2012 · CA
TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO$1,000,000
R44 · FY2014 · CA
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$999,580
R44 · FY2023 · HD
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$995,592
R44 · FY2024 · HD
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$991,379
R44 · FY2025 · HD
TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO$961,000
R44 · FY2013 · CA
TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO$949,265
R44 · FY2012 · CA
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$681,601
R44 · FY2019 · HD
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$602,718
R01 · FY2017 · CA
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$585,583
R01 · FY2018 · CA
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$546,766
R01 · FY2019 · CA
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$538,027
R01 · FY2021 · CA
TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO$535,024
R44 · FY2010 · CA
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$522,676
R01 · FY2022 · CA
TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO$480,058
R43 · FY2008 · CA
Targeted Oxygen Delivery to Wounds: Using a Novel, Tunable, Oxygen Delivery Tech$331,743
R43 · FY2010 · GM